CART Cell Therapy Toxicity
Source : https://www.ncbi.nlm.nih.gov/books/NBK592426/
Chimeric antigen receptor-T (CAR-T) cell therapy is a type of genetically modified immunotherapy that is directed at cancer cells.
Conclusions/Relevance: Despite the current success rate of CAR-T therapy, it comes with the caveat of significant toxicities. The most common adverse events (AEs) of CAR-T therapy, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), remain barriers to the use of CAR-T cell therapy....
Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
Source : https://www.sciencedirect.com/science/article/pii/S2666636723012344?via=ihub
Diffuse large B cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin lymphoma. Although outcomes to frontline therapy are encouraging, p...
Conclusions/Relevance: Barriers to referrals for CAR-T therapy are described, along with recommendations to improve collaboration between community oncologists and physicians from CAR-T therapy treatment centers and subsequent long-term care of patients in community treatment centers.
Conclusions: Patients with DLBCL and mental disorders had worse short-term and long-term mortality, particularly those with post-diagnosis mental disorders. Further studies are needed to examine mental health service utilization and factors mediating the relationship between mental disorders and inferior mortality.
Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality - Journal of Translational Medicine
Source : https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-023-04372-4
Chimeric antigen receptors (CARs) are engineered to target T cells specifically to tumor cells, resulting in the engineered T cell killing the tumor cell. This technology has been developed to...
Conclusions/Relevance: While there has been extensive preclinical and clinical work looking at CARs with a variety of targeting domains and architectures, this review will focus on the differences between the four marketed anti-CD19 CAR-Ts, with an additional focus on the impact of hinge and transmembrane domain on CAR activity and...
A retrospective head-to-head comparison of the Lugano Classification and PERCIST for FDG-PET/CT response assessment in diffuse large B-cell lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37501554/
The Lugano Classification and PERCIST were equally predictive of PFS. Non-response at interim and non-CMR at EOT were predictive of poor PFS with comparable accuracy for predicting events within two...
Conclusion: The Lugano Classification and PERCIST were equally predictive of PFS. Non-response at interim and non-CMR at EOT were predictive of poor PFS with comparable accuracy for predicting events within two years.